https://scholars.lib.ntu.edu.tw/handle/123456789/543526
標題: | An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer | 作者: | Chao Y. Li C.P. Chao T.Y. Su W.C. Hsieh R.K. Wu M.F. KUN-HUEI YEH Kao W.Y. Chen L.T. ANN-LII CHENG |
公開日期: | 2006 | 卷: | 95 | 期: | 2 | 起(迄)頁: | 159-163 | 來源出版物: | British Journal of Cancer | 摘要: | The aim of the study was to evaluate the response rate and safety of weekly paclitaxel (Taxol?) combination chemotherapy with UFT (tegafur, an oral 5-fluorouracil prodrug, and uracil at a 1 : 4 molar ratio) and leucovorin (LV) in patients with advanced gastric cancer. Patients with histologically confirmed, locally advanced or recurrent/metastatic gastric cancer were studied. Paclitaxel 1-h infusion at a dose of 100 mg m-2 on days 1 and 8 and oral UFT 300 mg m- day-1 plus LV 90 mg day-1 were given starting from day 1 for 14 days, followed by a 7-day period without treatment. Treatment was repeated every 21 days. From February 2003 to October 2004, 55 patients were enrolled. The median age was 62 years (range: 32-82). Among the 48 patients evaluated for tumour response, two achieved a complete response and 22 a partial response, with an overall response rate of 50% (95% confidence interval: 35-65%). All 55 patients were evaluated for survival and toxicities. Median time to progression and overall survival were 4.4 and 9.8 months, respectively. Major grade 3-4 toxicities were neutropenia in 25 patients (45%) and diarrhoea in eight patients (15%). Although treatment was discontinued owing to treatment-related toxicities in nine patients (16%), there was no treatment-related mortality. Weekly paclitaxel plus oral UFT/LV is effective, convenient, and well tolerated in treating patients with advanced gastric cancer. ? 2006 Cancer Research. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745960387&doi=10.1038%2fsj.bjc.6603225&partnerID=40&md5=c144591d96cf7084a2d95d58dca68021 https://scholars.lib.ntu.edu.tw/handle/123456789/543526 |
ISSN: | 0007-0920 | DOI: | 10.1038/sj.bjc.6603225 | SDG/關鍵字: | cimetidine; dexamethasone; diphenhydramine; folinic acid; paclitaxel; UFT; adult; advanced cancer; aged; alopecia; anemia; anorexia; article; body weight disorder; cancer adjuvant therapy; cancer combination chemotherapy; cancer localization; cancer patient; cancer recurrence; cancer surgery; cardiotoxicity; chemotherapy induced emesis; clinical trial; confidence interval; controlled clinical trial; controlled study; diarrhea; disease course; drug dose reduction; drug efficacy; drug fatality; drug fever; drug infusion; drug safety; drug tolerability; drug withdrawal; evaluation; febrile neutropenia; female; follow up; histopathology; human; hypesthesia; leukopenia; major clinical study; male; metastasis; multicenter study; nausea; neutropenia; overall survival; phase 2 clinical trial; priority journal; sample size; sensory neuropathy; sinus tachycardia; stomach cancer; stomatitis; survival time; therapy effect; thrombocytopenia; treatment response; weight reduction; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Leucovorin; Male; Middle Aged; Paclitaxel; Prospective Studies; Safety; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome; Uracil |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。